Activity

Parathyroid carcinoma is one of the least frequent malignant neoplasms, diagnosis and treatment are often complex; however, the prognosis is not bad and, although recurrences are frequent, the mortality rate is low. We describe the clinical case of a 42-years-old patient, the evolution of the natural history and treatment.

Knowledge Translation (KT) is defined as the synthesis, exchange and application of knowledge to foster the benefits of global and local innovation. In healthcare and medicine, KT is an increasingly relevant topic, as recognized by the growing number of publications. While the traditional definition of KT recalls the need to translate scientific research into clinical practice, other types of KT emerge. More in details, they concern the interaction of actors with different skills and feelings, who find themselves working together to achieve a common outcome. The paper aims to understand the dynamics and tools of KT by analyzing the case of an Italian Breast Unit.

The paper uses a methodology based on a case study relating to the IRCCS CRO – National Care Institute Center for Oncological Reference of Aviano. Multiple information sources are used to collect, triangulate, and verify data.

The analysis allows to divide the stakeholders into two groups a first professional or internal group, characterized by a common healthcare background, and a second non-professional or external group, which gathers actors with various skills, needs, and feelings. The two groups use profoundly different tools and methodologies to translate knowledge effectively.

While the first group translates knowledge internally using more explicit tooles, and benefits from the team’s durability, the second group needs more creative methodologies, many of which are based on language and interpersonal skills. The temporary nature of relations with the BU of this latter group requires the use of always different and innovative tools.

While the first group translates knowledge internally using more explicit tooles, and benefits from the team’s durability, the second group needs more creative methodologies, many of which are based on language and interpersonal skills. Bemcentinib price The temporary nature of relations with the BU of this latter group requires the use of always different and innovative tools.

Pemetrexed maintenance significantly improved progression-free survival (PFS) and overall survival (OS) in advanced nonsquamous non-small-cell lung cancer (NSCLC) patients not progressing after induction chemotherapy.

This study is aimed at examine the association of various clinical factor and survival in a real-world cohort analysis.

One hundred ninety-four patients were included and classified as “PM” cohort (“Pemetrexed Maintenance”, including patients given with pemetrexed maintenance after induction chemotherapy, n=112), and “noPM” cohort (“no Pemetrexed Maintenance” including those discontinuing pemetrexed, n=82).

The median PFS was 8.8 and 5.4 months in the PM and noPM cohorts, respectively (p=0.001). The median OS was 19.6 months in the “PM” cohort and 13.2 months in the “noPM” cohort (p<0.02). In the multivariate analysis, ECOG Performance Status (PS) 0 and maintenance therapy were independently associated with improved PFS and OS. A longer median PFS was reported in patients given ≥5 cycles of pemetrexed maintenance (p<0.01).

These results further confirm the survival benefit of pemetrexed maintenance in a real-word population. All eligible advanced NSCLC patients should be strongly considered for at least 5 of pemetrexed maintenance.

These results further confirm the survival benefit of pemetrexed maintenance in a real-word population. All eligible advanced NSCLC patients should be strongly considered for at least 5 of pemetrexed maintenance.The incidence of non-melanoma skin cancers (NMSC) is increasing worldwide and these skin cancers have become an important health issue. An integrated care pathway (ICP) is a multidisciplinary outline of anticipated care, placed in an appropriate timeframe, to help a patient with a specific condition. The aim of this paper is to define the ICP for patients affected by NMSC referring to the Istituto Dermopatico dell’Immacolata – IRCCS of Rome and Villa Paola, Italy. This ICP is multidisciplinary and included various specialists like dermatologist, oncologist, general surgeon, plastic surgeon, anatomopathologist, molecular biologist and epidemiologist. This ICP is based on the most recent acquisitions in the literature, referring in particular to the national (EADO and SIDEMAST) and international guidelines (EDF and NCCN). We firstly valued the current practice for patients affected by NMSC referring to our Institute to define the multidisciplinary process map. This process delineated the activities and the responsibilities performed during delivery of care to the patients and the potential problem areas or opportunities for improvements. Subsequently, we defined the final ICP process. This ICP of NMSC represents an innovative strategy to provide high quality healthcare. This allows to ensure all the necessary procedures for the patient, optimizing the “continuum” of care and the use of health services, and improving the organization of the Institute regarding an important health issue.

Medical records are a relevant source for real-world evidence. We introduced patient-reported outcomes (PROs) in clinical practice, demonstrating a significant quality-of-life improvement, compared to usual visit. In this secondary analysis, we describe the agreement between patients’ and physicians’ reports of 5 symptoms. Our hypothesis was that adoption of PROs questionnaire could significantly improve the agreement.

Eligible patients were receiving active anti-cancer treatment. Patients in the control group underwent usual visits (group A), while patients of group B, before each visit, filled a PROs paper questionnaire, to provide information about symptoms and toxicities. No specific instructions were provided to physicians to integrate such information in medical records. Agreement between patient and physician evaluations was assessed by Cohen’s κ, calculating under-reporting as proportion of toxicities reported by patients but not recorded by physicians.

211 patients (412 visits) have been analyzed.